Jefferies initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $31 price target Summit’s “first-in-class” Ivonescimab “leads the pack” to challenge PD-(L)1 inhibitors, which the analyst identifies as “the most valuable oncology drug class.” The firm, which says the near-term focus is on the first global data in NSCLC in mid-2025 and overall survival data in mid-2025, sees about $10B peak sales “in NSCLC alone,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMMT:
- Biotech Alert: Searches spiking for these stocks today
- TipRanks’ ‘Perfect 10’ Picks: 2 Top-Scoring Stocks for the Rest of 2024
- Summit Therapeutics initiated with an Outperform at JMP Securities
- Summit Therapeutics price target lowered to $44 from $45 at H.C. Wainwright
- Summit Therapeutics Advances NSCLC Trials and Strengthens Financials